SCHEMBL24914932

SCHEMBL24914932

CCOC(=O)c1cc(CO[Si](C)(C)C(C)(C)C)nn1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
MAPT P10636 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 5/20 0.38
FAAH O00519 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ESR1 P03372 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
POLB P06746 2/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7703155 0.82 LMNA (0.47) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL30673263 0.81 ALDH1A1 (0.41) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20521782 0.81 SMN1; SMN2 (0.44) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL25348368 0.80 SMN1; SMN2 (0.45) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL973113 0.80 LMNA (0.50) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL26964701 0.79 RAB9A (0.44) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL7699075 0.79 LMNA (0.49) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL31206724 0.79 ALDH1A1 (0.43) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL23546779 0.78 MPO (0.42) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL859 0.77 POLB (0.50) LMNASMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
EP-4122927-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF ADORA2A, ADORA2B, ADORA3 LMNA 3817/4885SMN1; SMN2 3350/4885RAB9A 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.